MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine

MSC 2013：成体干细胞治疗和再生医学

• 批准号: 8597780
• 负责人: STANTON L. GERSON
• 金额: $ 2.5万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-02 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8597780
• 关键词: Adult; Award; Biotechnology; Cell Therapy; Clinic; Clinical; Clinical Sciences; Clinical Trials; Devices; Disadvantaged; Doctor of Medicine; Doctor of Philosophy; Drug usage; Electronic Mail; Event; Funding; Goals; Industry; Knowledge; Laboratory Research; Lead; Link; Master of Business Administration; Medical center; Medicine; Minority; Oral; Organ; Physicians; Population; Postdoctoral Fellow; Principal Investigator; Quality of life; Regenerative Medicine; Reporting; Research; Research Personnel; Risk; Shapes; Stem Cell Research; Stem cells; Students; Technology; Therapeutic; Tissue Engineering; Tissues; Translating; Translational Research; Travel; Universities; University Hospitals; Vision; Woman; Work; Writing; adult stem cell; animal tissue; career development; cell preparation; cell type; clinical application; clinical research site; experience; graduate student; human tissue; improved; improved functioning; innovation; interest; lectures; medical schools; meetings; patient population; posters; pre-clinical; product development; programs; public health relevance; repaired; scaffold; stem cell technology; stem cell therapy; symposium; Adult; Award; Biotechnology; Cell Therapy; Clinic; Clinical; Clinical Sciences; Clinical Trials; Devices; Disadvantaged; Doctor of Medicine; Doctor of Philosophy; Drug usage; Electronic Mail; Event; Funding; Goals; Industry; Knowledge; Laboratory Research; Lead; Link; Master of Business Administration; Medical center; Medicine; Minority; Oral; Organ; Physicians; Population; Postdoctoral Fellow; Principal Investigator; Quality of life; Regenerative Medicine; Reporting; Research; Research Personnel; Risk; Shapes; Stem Cell Research; Stem cells; Students; Technology; Therapeutic; Tissue Engineering; Tissues; Translating; Translational Research; Travel; Universities; University Hospitals; Vision; Woman; Work; Writing; adult stem cell; animal tissue; career development; cell preparation; cell type; clinical application; clinical research site; experience; graduate student; human tissue; improved; improved functioning; innovation; interest; lectures; medical schools; meetings; patient population; posters; pre-clinical; product development; programs; public health relevance; repaired; scaffold; stem cell technology; stem cell therapy; symposium

DESCRIPTION (provided by applicant): MSC 2013 is being presented by: The National Center for Regenerative Medicine (NCRM), the Cleveland Clinical and Translational Science Consortium (CTSC), Case Western Reserve University School of Medicine (CWRUSOM), Cleveland Clinic (CC), and University Hospitals Case Medical Center (UHCMC). MSC 2013 will take place in Cleveland, OH, August 19-21, 2013 at the Cleveland Marriott Downtown at Key Center. MSC 2013 Conference Directors include Arnold Caplan, Ph.D.; Robert Deans, Ph.D.; Stanton Gerson, M.D.; Jan Nolta, Ph.D.; Frank Barry, Ph.D.; Mahendra Rao, M.B.B.S., Ph.D.; and Michael Gilkey, M.B.A., M.S. The Conference Directors were chosen due to their active, world-renowned statures in adult stem cell research as well as geographic diversity. Numerous planning meetings and email discussions have already occurred and have shaped the program to serve the field they lead. Vision Statement MSC 2013 will have platform and poster sessions emphasizing preclinical and clinical applications of adult- derived stem cells from a variety of human and animal tissues. MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. Target Audience Innovators in the use of stem cells in regenerative medicine The target audience is multi-fold: new and experienced investigators in the adult stem cell therapy field, students (graduate and post-doctoral), physicians, and commercial entities interested in therapeutic opportunities with these cell types. Junior investigators and students will be given a venue to present and discuss their research in poster sessions and invited presentations. Conference Objectives MSC 2013 will * Offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. * Focus on the isolation, characterization, purity, plasticity and clinical uses of adult-derived stem cells from a variety of human and animal tissues. * Emphasize state-of-the-art technologies and clinical utility of these cell preparations for tissue engineering and regenerative medicine. * Feature invited lectures from thought-leaders and provide platform sessions, poster sessions, and a venue for junior investigators and students to present and discuss their research. * Provide a regulatory approach to product development - FDA, commercial risks, endpoints, and patient populations. * Link biotechnology cell therapy industry to investigators and clinical sites including clinical trial status reports. Proposal Specific Aim The specific aim of this R13 proposal is to provide travel and registration support for graduate students, postdoctoral students and clinical fellows to attend MSC 2013, with an emphasis on supporting the participation of women and minority populations. An important consideration is the diversification and participation of students and fellows, so funds will be allocated for disadvantaged and under-represented students to attend the meeting. The goal is to improve career development in the field of regenerative medicine, including broadening their knowledge in stem cell technology and interacting with funded principal investigators. All applicants will be required to submit a poster for presentation and those chosen will present their work at MSC 2013. We plan to provide travel awards for approximately 20 graduate students and post- doctoral fellows to attend and "actively" participate in MSC 2013 through oral and poster presentations, networking events and co-chairing of sessions. They will also be asked to help write the conference proceedings in concert with our Conference Directors.

描述（由申请人提供）：MSC 2013由：国家再生医学中心（NCRM），克利夫兰临床和转化科学财团（CTSC），凯斯西部储备大学医学院（CWRUSOM），克利夫兰诊所（CC）和大学医院医院医疗中心（UHCMC）。 2013年MSC 2013将于2013年8月19日至21日在俄亥俄州克利夫兰举行，位于Key Center的Cleveland Marriott市区。 MSC 2013会议主管包括Arnold Caplan博士；罗伯特·迪恩斯（Robert Deans）博士； Stanton Gerson，医学博士； Jan Nolta博士；弗兰克·巴里（Frank Barry）博士； Mahendra Rao，M.B.B.S.，博士；和迈克尔·吉尔基（Michael Gilkey），硕士会议主管因其在成人干细胞研究和地理多样性方面的积极，世界知名的结论而被选中。已经进行了许多计划会议和电子邮件讨论，并塑造了该计划的服务，以服务他们领导的领域。 愿景陈述 MSC 2013将举办平台和海报会议，强调来自各种人类和动物组织的成年干细胞的临床前和临床应用。 MSC 2013将提供一个论坛，以交流和讨论转化再生医学的研究，思想和尖锐突破。 目标受众 在再生医学中使用干细胞的创新者 目标受众是多重的：成人干细胞疗法领域的新的和经验丰富的研究人员，学生（研究生和博士后），医生以及对这些细胞类型的治疗机会感兴趣的商业实体。初级调查人员和学生将在海报会议和邀请演讲中介绍和讨论他们的研究。 会议目标 MSC 2013 Will *提供一个论坛，以交流和讨论转化再生医学中的研究，思想和尖锐突破。 *专注于各种人类和动物组织的成人干细胞的分离，表征，纯度，可塑性和临床用途。 *强调这些细胞工程和再生医学的细胞制剂的最先进技术和临床实用性。 *特征来自思想领袖的邀请演讲，并提供平台会议，海报会议以及初级调查员和学生的场所，供初级调查员和学生介绍和讨论他们的研究。 *提供一种监管方法来开发产品 - FDA，商业风险，终点和患者人群。 *将生物技术细胞治疗行业与研究人员和临床部位联系起来，包括临床试验状态报告。 提案特定目标 该R13提案的具体目的是为研究生，博士后学生和临床研究员提供旅行和注册支持，以参加2013年MSC，重点是支持妇女和少数群体的参与。一个重要的考虑因素是学生和研究员的多元化和参与，因此将为处境不利和代表性不足的学生分配资金参加会议。目的是改善再生医学领域的职业发展，包括扩大其在干细胞技术方面的知识并与资助的主要研究人员互动。所有申请人都将 要求提交一张海报以进行演讲，而被选为的人将在MSC 2013上展示他们的作品。我们计划为大约20名研究生和博士后研究员提供旅行奖，以便参加并“积极地”通过口头和海报演示，网络活动，社交活动和会议的共同顾问参加MSC 2013。他们还将被要求帮助与我们的会议董事共同编写会议程序。